1. Francis DP, Gregory T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, Kitayaporn D, Pitisuttitham P, Matthews T, Schwartz DH, Berman PW: Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plan for phase 3. AIDS Res Hum Retroviruses. 1998, 14 (Suppl 3): S325-S331.
2. The HIV/AIDS Collaboration, Thailand: Annual Report for 2000–2001. Part C. HIV transmission among injecting drug users and HIV vaccine efficacy trial. 30-35.
3. Phanupak P, Teeratakulpixarn S, Sarangbin S, Nookhai S, Ubolyam S, Sirivichayabul S, Leesavan A, Forrest BD, Hanson CV, Li M, Wang CY, et al: International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allergy Immunol. 1997, 15 (1): 41-48.
4. Migasena S, Suntharasamai P, Pitisuttitham P, Kitayaporn D, Wasi C, Huang W, Vanichseni S, Koompong C, Kaewkungwal J, Raktham S, et al: AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization. AIDS Res Hum Retrovirus. 2000, 16 (7): 655-663.41-48. 10.1089/088922200308882.
5. Allen M, Israel H, Rybezyk K, Pugliese MA, Loughran K, Wagner L, Erb S: Trial-related discrimination in HIV vaccine clinical trials. AIDS RES Hum Retroviruses. 2001, 17 (8): 667-674. 10.1089/088922201750236942.